Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland and has exclusive IP rights until the mid-2030s. In Europe it is marketed as
Feraccru® with commercialisation led by Norgine BV and in the USA the product which benefits from NCE exclusivity until 2024 will be marketed as Accrufer®.
A busy start this morning at the 15th Congress of #ECCO2020 in Vienna. Mark Sampson our CMO is attending. If you wo… https://t.co/uROohRX5sf
RT @WalbrookPR: Tim Watts, CFO of @ShieldTx (AIM: #STX) presents to investors at The Growth and Innovation Forum #shares #cenkos https://t.…
RT @WalbrookPR: Come visit @ShieldTx (AIM: #STX) exhibiting at The Growth & Innovation Forum today: stand 6 #shares #cenkos https://t.co/j5…
